SMT201800221T1 - Metodo per ridurre i sintomi simil-influenzali associati alla somministrazione intramuscolare di interferone utilizzando un regime di dosaggio crescente a titolazione rapida - Google Patents

Metodo per ridurre i sintomi simil-influenzali associati alla somministrazione intramuscolare di interferone utilizzando un regime di dosaggio crescente a titolazione rapida

Info

Publication number
SMT201800221T1
SMT201800221T1 SM20180221T SMT201800221T SMT201800221T1 SM T201800221 T1 SMT201800221 T1 SM T201800221T1 SM 20180221 T SM20180221 T SM 20180221T SM T201800221 T SMT201800221 T SM T201800221T SM T201800221 T1 SMT201800221 T1 SM T201800221T1
Authority
SM
San Marino
Prior art keywords
interferon
symptoms associated
dosing regimen
intramuscular administration
escalating dosing
Prior art date
Application number
SM20180221T
Other languages
English (en)
Italian (it)
Inventor
Aaron Deykin
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of SMT201800221T1 publication Critical patent/SMT201800221T1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicinal Preparation (AREA)
SM20180221T 2011-03-15 2012-03-15 Metodo per ridurre i sintomi simil-influenzali associati alla somministrazione intramuscolare di interferone utilizzando un regime di dosaggio crescente a titolazione rapida SMT201800221T1 (it)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161452807P 2011-03-15 2011-03-15
US201161476930P 2011-04-19 2011-04-19
PCT/US2012/029201 WO2012125809A1 (en) 2011-03-15 2012-03-15 Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen
EP12719487.6A EP2686002B1 (en) 2011-03-15 2012-03-15 Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen

Publications (1)

Publication Number Publication Date
SMT201800221T1 true SMT201800221T1 (it) 2018-07-17

Family

ID=46045072

Family Applications (1)

Application Number Title Priority Date Filing Date
SM20180221T SMT201800221T1 (it) 2011-03-15 2012-03-15 Metodo per ridurre i sintomi simil-influenzali associati alla somministrazione intramuscolare di interferone utilizzando un regime di dosaggio crescente a titolazione rapida

Country Status (25)

Country Link
US (6) US9198955B2 (enExample)
EP (1) EP2686002B1 (enExample)
JP (2) JP6279905B2 (enExample)
KR (1) KR102050339B1 (enExample)
CN (1) CN103702680A (enExample)
AU (1) AU2012229104B2 (enExample)
BR (1) BR112013023609A8 (enExample)
CA (1) CA2846786C (enExample)
CY (1) CY1120176T1 (enExample)
DK (1) DK2686002T3 (enExample)
EA (1) EA028448B1 (enExample)
ES (1) ES2666850T3 (enExample)
HR (1) HRP20180621T1 (enExample)
HU (1) HUE036931T2 (enExample)
IL (1) IL228425A (enExample)
LT (1) LT2686002T (enExample)
MX (1) MX359947B (enExample)
PL (1) PL2686002T3 (enExample)
PT (1) PT2686002T (enExample)
RS (1) RS57175B1 (enExample)
SG (1) SG193446A1 (enExample)
SI (1) SI2686002T1 (enExample)
SM (1) SMT201800221T1 (enExample)
WO (1) WO2012125809A1 (enExample)
ZA (1) ZA201306933B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2846786C (en) * 2011-03-15 2022-05-17 Biogen Idec Inc. Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen
EP3092305B1 (en) 2014-01-09 2023-08-02 Kyushu University, National University Corporation Method of producing microglial cells
WO2018056584A1 (ko) 2016-09-21 2018-03-29 삼성전자 주식회사 피부 상태 측정 방법 및 이를 위한 전자 장치
WO2022069250A1 (en) * 2020-09-30 2022-04-07 Koninklijke Philips N.V. Methods and systems for performing dose titration

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4456748A (en) 1981-02-23 1984-06-26 Genentech, Inc. Hybrid human leukocyte interferons
WO1982002715A1 (fr) 1981-02-04 1982-08-19 Sugano Haruo Gene d'interferon (beta)humain
US4695543A (en) 1982-03-23 1987-09-22 Bristol-Myers Company Alpha Interferon GX-1
CA1302320C (en) 1984-06-11 1992-06-02 Hideo Niwa Expression of human cromosomal interferon-_ in animal cells
US5231176A (en) 1984-08-27 1993-07-27 Genentech, Inc. Distinct family DNA encoding of human leukocyte interferons
FI90990C (fi) 1984-12-18 1994-04-25 Boehringer Ingelheim Int Rekombinantti-DNA-molekyyli, transformoitu isäntäorganismi ja menetelmä interferonin valmistamiseksi
ATE78262T1 (de) 1985-06-11 1992-08-15 Ciba Geigy Ag Hybrid-interferone.
US5641656A (en) 1993-10-22 1997-06-24 University Of Connecticut Nucleic acids encoding avian interferon (IFN) proteins and recombinant methods using them
DE69729880T3 (de) * 1996-12-24 2012-05-10 Biogen Idec Ma Inc. Stabile flüssige interferon-zubereitungen
JP2001104482A (ja) * 1999-10-07 2001-04-17 Terumo Corp 2室型プレフィルドシリンジ
US8932265B2 (en) * 2003-01-30 2015-01-13 Becton, Dickinson And Company Holder with safety shield for a drug delivery device
US7731948B2 (en) * 2004-06-01 2010-06-08 Ares Trading S.A. Stabilized interferon liquid formulations
US20060089593A1 (en) * 2004-10-26 2006-04-27 Sergio Landau Needle-free injection device for individual users
EP1923085A1 (en) * 2006-11-17 2008-05-21 Sanofi-Aventis Deutschland GmbH Dosing and drive mechanism for drug delivery device
US8071544B2 (en) * 2006-12-18 2011-12-06 Althea Technologies, Inc. Crystallized recombinant human growth factor formulations
US9044378B2 (en) * 2007-05-31 2015-06-02 Safety Syringes, Inc. Anti-needle stick safety device or system for use with drugs requiring reconstitution
JP5549048B2 (ja) * 2007-08-16 2014-07-16 味の素株式会社 薬剤バイアルとプレフィルドシリンジの接続構造
MX2011013722A (es) * 2009-06-18 2012-05-08 Wyeth Llc Formulaciones liofilizadas para inmunofarmaceuticos modulares pequeños.
CA2846786C (en) * 2011-03-15 2022-05-17 Biogen Idec Inc. Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen

Also Published As

Publication number Publication date
EP2686002B1 (en) 2018-01-24
ES2666850T3 (es) 2018-05-08
MX359947B (es) 2018-10-17
NZ712273A (en) 2016-09-30
HUE036931T2 (hu) 2018-08-28
KR20140038383A (ko) 2014-03-28
IL228425A0 (en) 2013-12-31
AU2012229104B2 (en) 2017-03-16
SG193446A1 (en) 2013-10-30
DK2686002T3 (en) 2018-04-30
EA201301024A1 (ru) 2014-03-31
BR112013023609A2 (pt) 2016-12-06
NZ616536A (en) 2015-10-30
RS57175B1 (sr) 2018-07-31
US20200046804A1 (en) 2020-02-13
SI2686002T1 (en) 2018-06-29
AU2012229104A1 (en) 2013-10-03
US20170360890A1 (en) 2017-12-21
US9198955B2 (en) 2015-12-01
ZA201306933B (en) 2016-07-27
IL228425A (en) 2017-08-31
EP2686002A1 (en) 2014-01-22
PT2686002T (pt) 2018-04-23
US20120237479A1 (en) 2012-09-20
JP6522069B2 (ja) 2019-05-29
JP6279905B2 (ja) 2018-02-14
WO2012125809A1 (en) 2012-09-20
US20160101157A1 (en) 2016-04-14
CY1120176T1 (el) 2018-12-12
JP2014508174A (ja) 2014-04-03
BR112013023609A8 (pt) 2018-04-03
CA2846786A1 (en) 2012-09-20
LT2686002T (lt) 2018-05-10
KR102050339B1 (ko) 2019-11-29
MX2013010507A (es) 2014-04-30
HRP20180621T1 (hr) 2018-07-27
CA2846786C (en) 2022-05-17
US10500254B2 (en) 2019-12-10
CN103702680A (zh) 2014-04-02
US20250276042A1 (en) 2025-09-04
EA028448B1 (ru) 2017-11-30
PL2686002T3 (pl) 2018-10-31
JP2018030847A (ja) 2018-03-01
US20220280610A1 (en) 2022-09-08

Similar Documents

Publication Publication Date Title
SMT202500218T1 (it) Regime di dosaggio dell'anticorpo anti-alfa4beta7
EP2686759A4 (en) IMPROVED TOUCH SURFACE
PL3412323T3 (pl) Autowstrzykiwacz do wstrzykiwania epinefryny
TWI561292B (en) Plasma torch
PL2789456T3 (pl) Maszyna formująca opony o potrójnym bębnie i sposób przemieszczania w niej materiału
GB201112434D0 (en) A fuel injector
SG11201402773XA (en) Gas injector apparatus for plasma applicator
PL2731607T3 (pl) Sposób koordynacji czasu kolonoskopii, w którym podaje się kompozycję pikosiarczanową
SG10201600144YA (en) Method for detecting protein-protein interaction
GB2512214B (en) Multi-touch interface schemes
GB201119879D0 (en) Green computing heterogeneous computer system
SG11201401764PA (en) A tie for fixing an article to a surface
PL2714888T3 (pl) Rekombinowane drożdże
AP2014007438A0 (en) Fuel production apparatus
PT2574596E (pt) Válvula de distribuição
GB201208320D0 (en) Injector
EP2707592A4 (en) KRAFTSTOFFEINSPRITVENTIL
GB201106233D0 (en) Fuel injector
IL228425A0 (en) A method for reducing flu-like symptoms associated with intramuscular administration of interferon using a rapid titration regimen in increasing doses
EP2768760A4 (en) PALETTENGABEL
GB201113421D0 (en) Fuel injector
PT2574597E (pt) Válvula de distribuição
EP2736669A4 (en) SELF-FIRING LONG ARC FLASH PLASMA
EP2766665A4 (en) COMBUSTION CHAMBER WITH REDUCED EMISSIONS
DE102011119533B8 (de) Lineare Brennstoff-Förderweiche